Infections and solid organ transplant rejection: A cause-and-effect relationship?

Lancet Infectious Diseases

Volumn 2, Issue 9, 2002, Pages 539-549

  Cainelli, Francesca ^a,b   Vento, Sandro ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; VALACICLOVIR;

ADENOVIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENTEROVIRUS; GRAFT REJECTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PARVOVIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION;

EID: 0036723794     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00370-5     Document Type: Review

References (151)

1. Do mild infections trigger the rejection of renal allografts?
2. Viral syndromes and renal homograft rejection
3. Viral infections and renal transplant rejection
4. Association of renal allograft rejection with virus infections
5. Listeria sepsis immediately preceding renal transplant rejection
6. Virus infections and acute renal transplant rejection
7. Do urinary tract infections trigger chronic kidney transplant rejection in man?
8. Association between Streptococcus faecalis urinary infections and graft rejection in kidney transplantation
9. Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection
10. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients
11. Risk factors for chronic rejection in renal allograft recipients
12. Infection-associated cellular activation accelerates chronic renal allograft rejection in rats
13. Infections and reduced functioning kidney mass induce chronic rejection in rat kidney allografts
14. Late urinary-tract infection after renal transplantation
15. Urinary tract infections after renal transplantation: Do they matter?
16. Late urinary tract infection after transplantation: Prevalence, predisposition and morbidity
17. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis
18. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection
19. Predictors of late acute orthotopic heart transplant rejection
20. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis
21. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart
22. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy
23. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts
24. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction
25. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection. Diagnosis using the polymerase chain reaction
26. Association of viral genome with graft loss in children after cardiac transplantation
27. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation
28. CMV infection, class II antigen expression and human kidney allograft rejection
29. Demonstration by light microscopy of cytomegalovirus on a renal biopsy of a renal allograft recipient: Confirmation by immunohistochemistry and in situ hybridisation
30. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus
31. Cytomegalovirus infection. An etiological factor for rejection?
32. Does cytomegalovirus cause glomerular injury in renal allograft recipients?
33. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplant: A meta-analysis
34. Influence of donor factors other than serologic status on transmission of cytomegalovirus to renal transplant recipients
35. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses
36. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell from donor
37. Immunologic parameters as predictive factors of cytomegalovirus disease in renal allograft recipients
38. Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection
39. Cytomegalovirus infection in transplant recipients
40. The role of the tumour necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients
41. Glomerulopathy associated with cytomegalovirus viremia in renal allograft
42. Association of herpes virus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation
43. Glomerular transplant rejection: A distinctive pattern of early graft damage
44. CMV glomerulopathy: Controversial lesion
45. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy
46. The clinical significance of cytomegalovirus infections in renal transplant recipients
47. Cytomegalovirus disease in renal allograft recipients: A prospective study of the clinical features, risk factors, and impact on renal transplantation
48. Serological responses to cytomegalovirus during renal transplant rejection
49. Prognostic value of anti-cytomegalovirus IgM in kidney graft recipients
50. The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporineprednisone immunosuppression
51. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation
52. Cytomegalovirus detection in lung transplant biopsy samples by polymerase chain reaction
53. Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung
54. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation
55. Risk factors for chronic rejection: A clinical perspective
56. Risk factors for chronic rejection in renal allograft recipients
57. The hyperfiltration hypothesis in human renal transplantation
58. Sex and age effects in renal transplantation
59. Cytomegalovirus infections following renal transplantation-effects of antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study
60. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation
61. Cytomegalovirus as a risk factor in renal transplantation
62. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients
63. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
64. Effect of initial slow graft function on renal allograft rejection and survival
65. Elevated factor VIII as a marker for vascular type of rejection after renal transplantation
66. Circulating ICAM-1: Novel parameter of renal graft rejection
67. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients
68. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells
69. Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM1 in blood
70. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection
71. Adhesion molecules and rejection of renal allografts
72. Absence of association between cytomegalovirus infection and obliterative transplant arteriopathy in renal allograft rejection
73. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection
74. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells
75. Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells
76. CMV as an exacerbating agent in transplant vascular sclerosis: Potential immune-mediated mechanisms modelled in vitro
77. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall: A possible linkage with enhanced allograft arteriosclerosis
78. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts
79. Cytomegalovirus infection induces vascular injury in the rat
80. Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings
81. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy
82. Intracoronary ultrasound in cardiac transplant recipients: In vivo evidence of angiographically silent intimal thickening
83. Hypercholesterolemia in long-term survivors of heart tarsnplantation: An early marker of accelerated coronary disease
84. Correlation of donor characteristics with transplant coronary artery disease as assessed by intracoronary ultrasound and coronary angiography
85. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone
86. Accelerated arteriosclerosis in cardiac transplantation: Role of cytotoxic B-cell antibodies and hyperlipidemia
87. Acute rejection and coronary artery disease in long-term survivors of heart transplantation
88. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease
89. Cardiac allograft vasculopathy: Relationship with acute cellular rejection and histocompatibility
90. Influence of HLA compatibility on the incidence of cardiac allograft vasculopathy after heart transplantation
91. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients
92. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts
93. Cytomegalovirus nucleic acids in allografted hearts
94. Cytomegalovirus infection accelerates cardiacallograft vasculopathy: Correlation between angiographic and endomyocardial biopsy findings in heart transplant patients
95. Cytomegalovirus infection and allospecific cytotoxic activity of graft-infiltrating cells after heart transplantation
96. Risk factor analysis for the major hazards following heart transplantation - Rejection, infection, and coronary occlusive disease
97. On the relation between cytomegalovirus infection and rejection after heart transplantation
98. Determinants of graft arteriosclerosis after heart transplantation
99. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts
100. Combined human cytomegalovirus and hepatitis C virus infections increase the risk of allograft vascular disease in heart transplant recipients
101. Steroid-responsive bronchiolitis after human heart-lung transplantation
102. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation
103. Cytomegalovirus infection and survival in lung transplant recipients
104. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat
105. The spectrum of cytomegalovirus infection following heart-lung transplantation
106. Five years experience with heart-lung transplantation: Analysis of risk factors of rejection
107. Cytomegalovirus infection and pneumonitis: Impact after isolated lung transplantation
108. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation
109. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation
110. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts
111. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection
112. An association between cytomegalovirus infection and chronic rejection after liver transplantation
113. Recipient HLA-DR3, tumour necrosis factor-α promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are inter-related risk factors for chronic rejection of liver grafts
114. Predictive factors for portal fibrosis in pediatric liver transplant recipients
115. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation
116. Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients
117. The DNA sequence of human herpesvirus-6: Structure, coding content and genome evolution
118. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures
119. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: Suppression of interleukin-2 synthesis and cell proliferation
120. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection
121. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients
122. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection
123. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients
124. Human herpesvirus-6 infection after liver transplantation
125. Human herpesvirus-6 antigenemia after liver transplantation
126. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: Effects on cytomegalovirus and herpes simplex virus infections
127. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients
128. Recombinant leukocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients
129. Townevaccine-induced prevention of cytomegalovirus disease after renal transplants
130. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: A controlled trial
131. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients
132. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
133. Treatment of transplant rejection in the presence of cytomegalovirus viremia
134. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation
135. Cytomegalovirus infections following renal transplantation - Effects of antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study
136. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients
137. Abstension from treatment of low-level pp65 cytomegalovirus antigenemia after liver transplantation: A prospective study
138. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial
139. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
140. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus iv gancidovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomised, controlled trial
141. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
142. Human herpesvirus-6 in liver transplant recipients. Role in pathogenesis of fungal infections, neurologic complications, and outcome
143. A randomised, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
144. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
145. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
146. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment
147. Current antiviral therapy fails to prevent the pro-inflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack
148. Human cytomegalovirus late protein encoded by ie2: A trans-activator as well as a repressor of gene expression
149. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
150. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28+ mice
151. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment